Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026663 · ClinicalTrials.gov registry record
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 86
- Enrollment target
NCT00026663: Completed study, sponsored by National Cancer Institute (NCI).
NCT00026663 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026663 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 86 participants
- Enrollment target
Study Summary
This study will examine blood, bone marrow, tumor and tissue samples from patients with cancer to study tumor resistance to chemotherapy (drug treatment). Many patients with cancer improve initially with chemotherapy, but then have a disease relapse, after which their tumor no longer responds to treatment. Other patients tumors are drug-resistant from the start. The study will look for "resistance factors"-substances in blood and tissues that render tumors resistant to chemotherapy. The findings may provide information needed to develop methods of combating drug resistance. Patients with cancer who are 18 years or older may be eligible for this study. Participants will have 40 milliliters (3 tablespoons) of blood drawn at the beginning of the study; additional samples will be obtained periodically during the course of treatment. A small sample of tumor or normal tissue will be taken from patients who undergo surgery or tumor biopsy (removal of a small piece of tumor) for medical reasons or as part of a research treatment protocol. Patients who do not require surgery or biopsy may be asked permission to obtain a tumor sample. Depending on the location of the tumor, this may be done by: 1) withdrawing bone marrow through a small needle; 2) removing fluid from the chest or abdomen; 3) removing a small tumor sample through a needle; or 4) removing the sample with a small incision into or around the tumor. These procedures will be done only if they are of low risk to the patient.
Primary Outcome
Obtain sufficient number of samples for a given test.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2000-08-09 |
| Est. Completion | 2024-06-28 |
What the finished NCT00026663 record still lists
NCT00026663 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 86 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00026663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00026663 about?
NCT00026663 is a clinical study titled "Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance". This study will examine blood, bone marrow, tumor and tissue samples from patients with cancer to study tumor resistance to chemotherapy (drug treatment). Many patients with cancer improve initially with chemotherapy, but then have a disease relapse, after which their tumor no longer responds to tre...
What is the current status of trial NCT00026663?
This trial is currently completed. The enrollment target is 86 participants. The study started on 2000-08-09. Estimated completion is 2024-06-28.
Who is sponsoring clinical trial NCT00026663?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI